» Articles » PMID: 38179301

Benefits and Risks of Drug Combination Therapy for Diabetes Mellitus and Its Complications: a Comprehensive Review

Overview
Specialty Endocrinology
Date 2024 Jan 5
PMID 38179301
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetes is a chronic metabolic disease, and its therapeutic goals focus on the effective management of blood glucose and various complications. Drug combination therapy has emerged as a comprehensive treatment approach for diabetes. An increasing number of studies have shown that, compared with monotherapy, combination therapy can bring significant clinical benefits while controlling blood glucose, weight, and blood pressure, as well as mitigating damage from certain complications and delaying their progression in diabetes, including both type 1 diabetes (T1D), type 2 diabetes (T2D) and related complications. This evidence provides strong support for the recommendation of combination therapy for diabetes and highlights the importance of combined treatment. In this review, we first provided a brief overview of the phenotype and pathogenesis of diabetes and discussed several conventional anti-diabetic medications currently used for the treatment of diabetes. We then reviewed several clinical trials and pre-clinical animal experiments on T1D, T2D, and their common complications to evaluate the efficacy and safety of different classes of drug combinations. In general, combination therapy plays a pivotal role in the management of diabetes. Integrating the effectiveness of multiple drugs enables more comprehensive and effective control of blood glucose without increasing the risk of hypoglycemia or other serious adverse events. However, specific treatment regimens should be tailored to individual patients and implemented under the guidance of healthcare professionals.

Citing Articles

Enhancing diabetes therapy with pH-sensitive co-delivery of metformin hydrochloride and glipizide using MCM-48-based dual drug delivery system.

Dasgupta D, Patel A RSC Adv. 2025; 15(9):7191-7199.

PMID: 40052104 PMC: 11883462. DOI: 10.1039/d5ra00204d.


Oxidative Stress, Glutathione Insufficiency, and Inflammatory Pathways in Type 2 Diabetes Mellitus: Implications for Therapeutic Interventions.

Dawi J, Misakyan Y, Affa S, Kades S, Narasimhan A, Hajjar F Biomedicines. 2025; 13(1).

PMID: 39857603 PMC: 11762874. DOI: 10.3390/biomedicines13010018.


A prospective, multicentre study evaluating safety and efficacy of a fixed dose combination of Remogliflozin etabonate, Vildagliptin, and Metformin in Indian patients with type 2 diabetes mellitus (Triad-RMV).

Agarwal P, Bhushan D, Bhate A, Naik S, Adwani S, Kushwaha J Clin Diabetes Endocrinol. 2024; 10(1):49.

PMID: 39690416 PMC: 11654189. DOI: 10.1186/s40842-024-00210-8.


Advanced therapy to cure diabetes: mission impossible is now possible?.

Rohban R, Martins C, Esni F Front Cell Dev Biol. 2024; 12:1484859.

PMID: 39629270 PMC: 11611888. DOI: 10.3389/fcell.2024.1484859.


The role of GABA in type 1 diabetes.

Mick G, McCormick K Front Endocrinol (Lausanne). 2024; 15:1453396.

PMID: 39619323 PMC: 11604429. DOI: 10.3389/fendo.2024.1453396.


References
1.
Li C, Zhang J, Yu D, Zhang Q . Adding glimepiride to current insulin therapy increases high-molecular weight adiponectin levels to improve glycemic control in poorly controlled type 2 diabetes. Diabetol Metab Syndr. 2014; 6(1):41. PMC: 3994470. DOI: 10.1186/1758-5996-6-41. View

2.
Smith B, Adams L . Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol. 2011; 7(8):456-65. DOI: 10.1038/nrendo.2011.72. View

3.
Deshmukh V, Sathyanarayana S, Menon S, Patil S, Jones R, Uppal S . Safety and efficacy of initial combination of linagliptin and metformin in patients with type 2 diabetes: A subgroup analysis of Indian patients from a randomized, double-blind, placebo-controlled study. Indian J Endocrinol Metab. 2015; 19(2):256-61. PMC: 4319266. DOI: 10.4103/2230-8210.149319. View

4.
Boj-Carceller D . Proton pump inhibitors: impact on glucose metabolism. Endocrine. 2012; 43(1):22-32. DOI: 10.1007/s12020-012-9755-3. View

5.
Kuhadiya N, Malik R, Bellini N, Patterson J, Traina A, Makdissi A . Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus. Endocr Pract. 2013; 19(6):963-7. DOI: 10.4158/EP13065.OR. View